Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy.

Shults K, Flye-Blakemore L, Patterson BK, Elbeik T.

Future Virol. 2012 Aug;7(8):819-832.

2.

[Architectonics of cell subpopulations of peripheral blood in patients with autoimmune myocarditis: clinical and pathogenetic aspects].

Shogenov ZS, Kekenadze NN, Vorob'eva SE, Usik MP, Elbeik T, Akhmedilova KA, Mamonova EE, Matsuura E, Pal'tsev MA, Suchkov SV.

Ter Arkh. 2008;80(12):23-8. Russian.

PMID:
19227902
3.

[Post-infectious clinical-immunological syndrome and its place in clinical practice].

Cherepakhina NE, Shogenov ZS, Elbeik T, Akhmedilova KA, Agirov MM, Tabaksoeva ZhA, Ogneva EA, Matsuura E, Mukhin NA, Shoenfeld Y, Pal'tsev MA, Suchkov SV.

Ter Arkh. 2009;81(12):71-8. Review. Russian.

PMID:
20481055
4.

Molecular epidemiology of HIV-1 subtypes and drug resistant strains in Taiwan.

Lan YC, Elbeik T, Dileanis J, Ng V, Chen YJ, Leu HS, Cheng SH, Wong JC, Wong WW, Chen YM.

J Med Virol. 2008 Feb;80(2):183-91.

PMID:
18098141
5.

HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep/TaqMan test.

Elbeik T, Dalessandro R, Loftus RA, Beringer S.

Expert Rev Mol Diagn. 2007 Nov;7(6):723-53.

PMID:
18020903
6.
7.

Cancer-associated immune-mediated syndromes: Pathogenic values and clinical implementation.

Suchkov SV, Petrunin DD, Kostalevskaya AV, Kachkov IA, Elbeik T, Matsuura E, Paltsev MA.

Biomed Pharmacother. 2007 Jul;61(6):323-37. Epub 2007 Jul 5.

PMID:
17656060
8.

[Chronic pyelonephritis: immunopathogenesis and clinicodiagnostic value of its specific features].

Mazo EB, Vinnitskĭ LI, Litvinov VA, Cherepakhina NE, Burdakova IuA, Elbeik T, Mukhin NA, Pal'tsev MA, Suchkov SV.

Ter Arkh. 2007;79(1):85-9. Review. Russian. No abstract available.

PMID:
17385475
10.

HIV RNA testing in the context of nonoccupational postexposure prophylaxis.

Roland ME, Elbeik TA, Kahn JO, Bamberger JD, Coates TJ, Krone MR, Katz MH, Busch MP, Martin JN.

J Infect Dis. 2004 Aug 1;190(3):598-604. Epub 2004 Jul 7.

PMID:
15243937
11.
12.

[Modern methods immunological and genetical diagnostics in clinical practice].

Cuchkov SV, Moskalets OV, Cherepakhina NE, Burdakova IuA, Suntsova IG, Shumskiĭ VI, Shaĭkhaev GO, Elbeik T, Beringer S, Petrauskene O.

Ter Arkh. 2004;76(4):78-83. Review. Russian. No abstract available.

PMID:
15174330
13.

Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).

Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, Kuramoto K, Ng V, Valdes R Jr, Valsamakis A, Terrault NA.

J Clin Microbiol. 2004 Feb;42(2):563-9.

14.

Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M.

Ann Intern Med. 2003 Aug 19;139(4):258-66.

PMID:
12965981
15.

Global cost modeling analysis of HIV-1 and HCV viral load assays.

Elbeik T, Chen YM, Soutchkov SV, Loftus RA, Beringer S.

Expert Rev Pharmacoecon Outcomes Res. 2003 Aug;3(4):383-407. doi: 10.1586/14737167.3.4.383.

PMID:
19807450
16.

Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance.

Gleaves CA, Welle J, Campbell M, Elbeik T, Ng V, Taylor PE, Kuramoto K, Aceituno S, Lewalski E, Joppa B, Sawyer L, Schaper C, McNairn D, Quinn T.

J Clin Virol. 2002 Aug;25(2):205-16.

PMID:
12367656
17.

In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.

Elbeik T, Hoo BS, Campodonico ME, Dileanis J, Fay FF, Bortolozzi RL, Benetti MS, Fay OH, Marlowe N, Petrauskene O, Chernoff D, Smith L, Ng VL.

J Hum Virol. 2001 Nov-Dec;4(6):317-28.

PMID:
12082398
18.

Health care industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay.

Elbeik T, Loftus RA, Beringer S.

Expert Rev Mol Diagn. 2002 May;2(3):275-85.

PMID:
12050866
19.

Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5.

Elbeik T, Alvord WG, Trichavaroj R, de Souza M, Dewar R, Brown A, Chernoff D, Michael NL, Nassos P, Hadley K, Ng VL.

J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):330-9.

PMID:
11917236
20.
21.

Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.

Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA.

AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1685-9.

PMID:
10606091
22.

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, Kunachiwa W, Maneekarn N, Vongchan P, Corral LG, Elbeik T, Shen Z, Kaplan G.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1169-79.

PMID:
10480630
23.

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM.

AIDS. 1999 Apr 16;13(6):F35-43.

PMID:
10397555
24.

Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors.

Liegler TJ, Yonemoto W, Elbeik T, Vittinghoff E, Buchbinder SP, Greene WC.

J Infect Dis. 1998 Sep;178(3):669-79.

PMID:
9728534
25.

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.

Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffith BP, Katzenstein DA, Hammer SM.

J Infect Dis. 1998 Mar;177(3):625-33.

PMID:
9498441
26.

Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.

Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D'Aquila RT, Scott W, Griffith BP, Hammer SM, Katzenstein DA.

J Infect Dis. 1998 Mar;177(3):617-24.

PMID:
9498440
27.

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

Ann Intern Med. 1997 Jun 15;126(12):929-38.

PMID:
9182469
28.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS.

N Engl J Med. 1996 Oct 10;335(15):1091-8. Erratum in: N Engl J Med 1997 Oct 9;337(15):1097.

29.

Human immunodeficiency virus grown in CD4-expressing cells is associated with CD4.

Hartley CA, Gilbert MJ, Brigido L, Elbeik T, Levy JA, Crowe SM, Mills J.

J Gen Virol. 1996 Sep;77 ( Pt 9):2015-23.

PMID:
8810998
30.

Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.

Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, Johnson RP, Buchbinder SP, Walker BD.

AIDS Res Hum Retroviruses. 1996 May 1;12(7):585-92.

PMID:
8743084
31.

Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.

Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Buchbinder SP, Walker BD.

J Immunol. 1996 Apr 1;156(7):2616-23.

PMID:
8786327
32.

Plasma viral load, CD4+ cell counts, and HIV-1 production by cells.

Levy JA, Ramachandran B, Barker E, Guthrie J, Elbeik T.

Science. 1996 Feb 2;271(5249):670-1. No abstract available.

PMID:
8571134
33.

Activation of virus replication after vaccination of HIV-1-infected individuals.

Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB.

J Exp Med. 1995 Dec 1;182(6):1727-37.

34.
35.

Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.

Kahn JO, Steimer KS, Baenziger J, Duliege AM, Feinberg M, Elbeik T, Chesney M, Murcar N, Chernoff D, Sinangil F.

J Infect Dis. 1995 May;171(5):1343-7.

PMID:
7751714
36.
37.
38.

A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates.

Safrin S, Elbeik T, Mills J.

J Infect Dis. 1994 Apr;169(4):879-82.

PMID:
8133105
39.

Human immunodeficiency virus-infected monocyte-derived macrophages express surface gp120 and fuse with CD4 lymphoid cells in vitro: a possible mechanism of T lymphocyte depletion in vivo.

Crowe SM, Mills J, Elbeik T, Lifson JD, Kosek J, Marshall JA, Engleman EG, McGrath MS.

Clin Immunol Immunopathol. 1992 Nov;65(2):143-51.

PMID:
1356673
40.

Lack of evidence of occult human immunodeficiency virus in seronegative individuals at very high risk of infection.

Crowe SM, Elbeik T, Ulrich PP, Mills J, Moss A.

J Med Virol. 1991 Nov;35(3):160-4.

PMID:
1804928
41.

Supplemental Content

Loading ...
Support Center